• search hit 8 of 11
Back to Result List

Can innovation still be the main growth driver of the pharmaceutical industry?

  • In the period from the 1950s to 2013, the American Food and Drug Administration (FDA) approved 1346 new molecular entities (NMEs) or new biologics entities (NBEs). On average, the approval rate was 20 NMEs per year. In the past 40 years, the number of new drugs launched into the market increased slightly from 15 NMEs in the 1970s to 25–30 NMEs since the 1990s. The highest number of new drugs approved by FDA was in 1996 and 1997, which might be related to the enactment of the Prescription Drug User Fee Act (PDUFA) in 1993.

Download full text files

  • 339.pdf
    eng

Export metadata

Additional Services

Share in Twitter Search Google Scholar
Metadaten
Name:Schuhmacher, Alexander
DOI:https://doi.org/10.1007/978-3-319-12526-8_2
ISBN:978-3-319-12525-1
Erschienen in:Sustainable Development for the Healthcare Industry : Reprogramming the Healthcare Value Chain
Publisher:Springer
Place of publication:Cham
Editor:Pierre Morgon
Document Type:Part of a Book
Language:English
Year of Publication:2014
Pagenumber:30
First Page:39
Last Page:68
Catalogue entry:Im Katalog der Hochschule Reutlingen ansehen
Dewey Decimal Classification:610 Medizin, Gesundheit
Open Access:Nein
Licence (German):License Logo  Lizenzbedingungen Springer